🎯 Drug Targets

Browse 4 drug targets with druggability analysis, composite scores, and clinical context

4

Targets

0

High Druggability

0.64

Avg Score

15

Target Classes

Druggability Distribution

High: 0Medium: 0Low: 4Unknown: 0

Avg druggability score: 0.390

Clinical Pipeline

Approved: 1Phase III: 0Phase II: 2Phase I: 1Preclinical: 0

Total compounds: 8 · Approved: 0

Filtered by: class=GPCR, druggability=Low — 4 results

P2RY1 P2Y purinoreceptor 1 Phase 1

Gpcr Low Druggability

GPCR antagonists or agonists modulating purinergic signaling

GPR37 G-protein coupled receptor 37 Phase 4

Gpcr Low Druggability

GPR37 agonists or modulators would activate the receptor to promote dopaminergic neuron survival and neuroprotection, counteracting the neurodegeneration characteristic of Parkinson's disease. Ligands binding to GPR37 would enhance G-protein signaling cascades that support neuronal viability and function.

CX3CR1 C-X3-C Motif Chemokine Receptor 1 Phase 2

Gpcr Low Druggability

GPCR antagonist modulating microglial activation and neuroinflammation

CMKLR1 Chemokine-like Receptor 1 Phase 2

Gpcr Low Druggability

GPCR antagonist or agonist modulating chemerin signaling